Evidence map›Paper›PMID 40127437›Full record

ArticleJMIR dermatology2025

Exploring the Views of Dermatologists, General Practitioners, and Melanographers on the Use of AI Tools in the Context of Good Decision-Making When Detecting Melanoma: Qualitative Interview Study.

Brad Partridge, Nicole Gillespie, H Peter Soyer, Victoria Mar, Monika Janda

Abstract read
In one paragraph

Article in JMIR dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Comment on "Artificial Intelligence in melanoma research: a bibliometric analysis".International journal of surgery (London, England) · 2026
    Article
  2. Article
  3. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis.JID innovations : skin science from molecules to population health · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brad PartridgeCentre for Health Services Research, University of Queensland, Brisbane, Australia.ORCID 0000-0002-4702-2923
Nicole GillespieMelbourne Business School, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-6101-2123
H Peter SoyerFrazer Institute, Dermatology Research Centre, University of Queensland, Brisbane, Australia.ORCID 0000-0002-4770-561X
Victoria MarVictorian Melanoma Service, Alfred Health, Melbourne, Australia.ORCID 0000-0001-9423-3435
Monika JandaCentre for Health Services Research, University of Queensland, Brisbane, Australia.ORCID 0000-0002-1728-8085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence that artificial intelligence (AI) may improve melanoma detection has led to calls for increased human-AI collaboration in clinical workflows. However, AI-based support may entail a wide range of specific functions for AI. To appropriately integrate AI into decision-making processes, it is crucial to understand the precise role that clinicians see AI playing within their clinical deliberations.

objectiveThis study aims to provide an in-depth understanding of how a range of clinicians involved in melanoma screening and diagnosis conceptualize the role of AI within their decision-making and what these conceptualizations mean for good decision-making.

methodsThis qualitative exploration used in-depth individual interviews with 30 clinicians, predominantly from Australia and New Zealand (n=26, 87%), who engaged in melanoma detection (n=17, 57% dermatologists; n=6, 20% general practitioners with an interest in skin cancer; and n=7, 23% melanographers). The vast majority of the sample (n=25, 83%) had interacted with or used 2D or 3D skin imaging technologies with AI tools for screening or diagnosis of melanoma, either as part of testing through clinical AI reader studies or within their clinical work.

resultsWe constructed the following 5 themes to describe how participants conceptualized the role of AI within decision-making when it comes to melanoma detection: theme 1 (integrative theme)-the importance of good clinical judgment; theme 2-AI as just one tool among many; theme 3-AI as an adjunct after a clinician's decision; theme 4-AI as a second opinion for unresolved decisions; theme 5-AI as an expert guide before decision-making. Participants articulated a major conundrum-AI may benefit inexperienced clinicians when conceptualized as an "expert guide," but overreliance, deskilling, and a failure to recognize AI errors may mean only experienced clinicians should use AI "as a tool." However, experienced clinicians typically relied on their own clinical judgment, and some could be wary of allowing AI to "influence" their deliberations. The benefit of AI was often to reassure decisions once they had been reached by conceptualizing AI as a kind of "checker," "validator," or in a small number of equivocal cases, as a genuine "second opinion." This raised questions about the extent to which experienced clinicians truly seek to "collaborate" with AI or use it to inform decisions.

conclusionsClinicians conceptualized AI support in an array of disparate ways that have implications for how AI should be incorporated into clinical workflows. A priority for clinicians is the conservation of good clinical acumen, and our study encourages a more focused engagement with users about the precise way to incorporate AI into the clinical decision-making process for melanoma detection.

Indexed as

Artificial IntelligenceAttitude of Health PersonnelClinical Decision-MakingDermatologistsGeneral PractitionersMelanomaSkin NeoplasmsAustraliaEarly Detection of CancerFemaleHumansInterviews as TopicMaleMiddle AgedNew ZealandQualitative Researchartificial intelligenceattitudesAustraliadecision-makingdecision supportdermatologistsgeneral practitionersmelanographersmelanomaNew Zealandqualitativeskin cancer

Identifiers

PMID40127437
PMCPMC11976179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.